Cargando…

Mortality in men with castration‐resistant prostate cancer—A long‐term follow‐up of a population‐based real‐world cohort

OBJECTIVES: The objective of this study is to find clinical variables that predict the prognosis for men with castration‐resistant prostate cancer (CRPC) in a Swedish real‐life CRPC cohort, including a risk group classification to clarify the risk of succumbing to prostate cancer. This is a natural...

Descripción completa

Detalles Bibliográficos
Autores principales:	Khoshkar, Yashar, Westerberg, Marcus, Adolfsson, Jan, Bill‐Axelson, Anna, Olsson, Henrik, Eklund, Martin, Akre, Olof, Garmo, Hans, Aly, Markus
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2021
Materias:	ORIGINAL ARTICLES
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8988790/ https://www.ncbi.nlm.nih.gov/pubmed/35474724 http://dx.doi.org/10.1002/bco2.116

Ejemplares similares

Modeling Disease Trajectories for Castration-resistant Prostate Cancer Using Nationwide Population-based Data
por: Ventimiglia, Eugenio, et al.
Publicado: (2022)

A drug comorbidity index to predict mortality in men with castration resistant prostate cancer
por: Fallara, Giuseppe, et al.
Publicado: (2021)

Variation in Prostate-Specific Antigen Testing Rates and Prostate Cancer Treatments and Outcomes in a National 20-Year Cohort
por: Bergengren, Oskar, et al.
Publicado: (2021)

Mortality following Hip Fracture in Men with Prostate Cancer
por: Van Hemelrijck, Mieke, et al.
Publicado: (2013)

Causes of death in men with localized prostate cancer: a nationwide, population‐based study
por: Van Hemelrijck, Mieke, et al.
Publicado: (2015)

Changes in Characteristics of Men with Lethal Prostate Cancer During the Past 25 Years: Description of Population-based Deaths
por: Lycken, Magdalena, et al.
Publicado: (2022)

Risk of thromboembolic diseases in men with prostate cancer: results from the population-based PCBaSe Sweden
por: Van Hemelrijck, Mieke, et al.
Publicado: (2010)

Long-term Outcomes Among Men Undergoing Active Surveillance for Prostate Cancer in Sweden
por: Ventimiglia, Eugenio, et al.
Publicado: (2022)

Is there any association between prostate-specific antigen screening frequency and uptake of active surveillance in men with low or very low risk prostate cancer?
por: Beckmann, Kerri, et al.
Publicado: (2019)

Association Between Antidiabetic Medications and Prostate-Specific Antigen Levels and Biopsy Results
por: Beckmann, Kerri, et al.
Publicado: (2019)

Population-based study on use of chemotherapy in men with castration resistant prostate cancer
por: Lissbrant, Ingela Franck, et al.
Publicado: (2013)

Real-world use of enzalutamide in men with nonmetastatic castration-resistant prostate cancer in Japan
por: Yokomizo, Akira, et al.
Publicado: (2021)

Real-World Treatment Patterns in Men with Castration- Resistant Prostate Cancer Receiving Docetaxel
por: Davis, Keith L., et al.
Publicado: (2015)

Use of 5α-reductase inhibitors for lower urinary tract symptoms and risk of prostate cancer in Swedish men: nationwide, population based case-control study
por: Robinson, David, et al.
Publicado: (2013)

Correction to: Real-world use of enzalutamide in men with nonmetastatic castration-resistant prostate cancer in Japan
por: Yokomizo, Akira, et al.
Publicado: (2022)

Variations in the Uptake of Active Surveillance for Prostate Cancer and Its Impact on Outcomes
por: Ahlberg, Mats S., et al.
Publicado: (2023)

Real-world evaluation of upfront docetaxel in metastatic castration-sensitive prostate cancer
por: Isaksson, Jenny, et al.
Publicado: (2021)

Real‐world outcomes of sipuleucel‐T treatment in PROCEED, a prospective registry of men with metastatic castration‐resistant prostate cancer
por: Higano, Celestia S., et al.
Publicado: (2019)

Determinants for choosing and adhering to active surveillance for localised prostate cancer: a nationwide population-based study
por: Bergengren, Oskar, et al.
Publicado: (2019)

Satisfaction with Nurse-led Follow-up in Prostate Cancer Patients—A Nationwide Population-based Study
por: Bergengren, Oskar, et al.
Publicado: (2022)

(177)Lu-Prostate-Specific Membrane Antigen Ligand After (223)Ra Treatment in Men with Bone-Metastatic Castration-Resistant Prostate Cancer: Real-World Clinical Experience
por: Sartor, Oliver, et al.
Publicado: (2022)

Identifying Prostate Cancer Among Men with Lower Urinary Tract Symptoms
por: Nordström, Tobias, et al.
Publicado: (2021)

Changes in lifestyle among prostate cancer survivors: A nationwide population‐based study
por: Bergengren, Oskar, et al.
Publicado: (2020)

The Management of Metastatic Castrate-Sensitive Prostate Cancer: From Guidelines to Real-World Practice
por: Gebrael, Georges, et al.
Publicado: (2023)

Real-World Outcomes in First-Line Treatment of Metastatic Castration-Resistant Prostate Cancer: The Prostate Cancer Registry
por: Chowdhury, Simon, et al.
Publicado: (2020)

Abiraterone acetate in metastatic castration-resistant prostate cancer – the unanticipated real-world clinical experience
por: Poon, Darren M. C., et al.
Publicado: (2016)

Management of Patients with Metastatic Castration-Sensitive Prostate Cancer in the Real-World Setting in the United States
por: Ryan, Charles J., et al.
Publicado: (2021)

Real‐world first‐line systemic therapy patterns in metastatic castration‐resistant prostate cancer
por: Anton, Angelyn, et al.
Publicado: (2021)

Association of Gonadotropin-Releasing Hormone Agonists for Prostate Cancer With Cardiovascular Disease Risk and Hypertension in Men With Diabetes
por: Lin, E., et al.
Publicado: (2022)

Survival Trend in Individuals With De Novo Metastatic Prostate Cancer After the Introduction of Doublet Therapy
por: Corsini, Christian, et al.
Publicado: (2023)

Prediction of metastatic prostate cancer by prostate-specific antigen in combination with T stage and Gleason Grade: Nationwide, population-based register study
por: Thomsen, Frederik B., et al.
Publicado: (2020)

First-line treatment of metastatic castration-resistant prostate cancer: the real-world Italian cohort of the Prostate Cancer Registry
por: Galli, Luca, et al.
Publicado: (2022)

Association between duration and type of androgen deprivation therapy and risk of diabetes in men with prostate cancer
por: Crawley, Danielle, et al.
Publicado: (2016)

The STHLM3-model, Risk-based Prostate Cancer Testing Identifies Men at High Risk Without Inducing Negative Psychosocial Effects
por: Koitsalu, Marie, et al.
Publicado: (2021)

Outcomes and toxicity of oral Fosfestrol in metastatic castration-resistant prostate cancer—a real-world experience
por: Nandini Devi, R, et al.
Publicado: (2023)

Risk of esophageal and gastric adenocarcinoma in men receiving androgen deprivation therapy for prostate cancer
por: Shore, Richard, et al.
Publicado: (2021)

Diagnostic activity impacts lifetime risk of prostate cancer diagnosis more strongly than life expectancy
por: Orrason, Andri Wilberg, et al.
Publicado: (2022)

Prostate-specific antigen response and clinical progression-free survival in Black and White men with chemotherapy-naïve metastatic castration-resistant prostate cancer treated with enzalutamide in a real-world setting
por: Freedland, Stephen J., et al.
Publicado: (2022)

Are Prostate Specific-Antigen (PSA) and age associated with the risk of ISUP Grade 1 prostate cancer? Results from 72 996 individual biopsy cores in 6 083 men from the Stockholm3 study
por: Palsdottir, Thorgerdur, et al.
Publicado: (2019)

The Value of Real-World Data in Understanding Prostate Cancer Risk and Improving Clinical Care: Examples from Swedish Registries
por: Beckmann, Kerri, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_i8uef93sjmjr5fc3t6faivsd1k